Brown Brothers Harriman & Co’s Relmada Therapeutics RLMD Stock Holding History

Brown Brothers Harriman & Co’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,000	Closed	-$9.72K	–	1557
2024 Q3	$9.72K	Hold	3,000	–	–	﹤0.01%	1058
2024 Q2	$9K	Hold	3,000	–	–	﹤0.01%	981
2024 Q1	$13.9K	Hold	3,000	–	–	﹤0.01%	945
2023 Q4	$12.4K	Hold	3,000	–	–	﹤0.01%	919
2023 Q3	$9K	Hold	3,000	–	–	﹤0.01%	967
2023 Q2	$7.38K	Hold	3,000	–	–	﹤0.01%	1005
2023 Q1	$6.78K	Hold	3,000	–	–	﹤0.01%	1029
2022 Q4	$10.5K	Hold	3,000	–	–	﹤0.01%	1011
2022 Q3	$111K	Hold	3,000	–	–	﹤0.01%	573
2022 Q2	$57K	Hold	3,000	–	–	﹤0.01%	683
2022 Q1	$81K	Sell	3,000 -3,000	-50%	-$62K	﹤0.01%	662
2021 Q4	$135	Hold	6,000	–	–	﹤0.01%	546
2021 Q3	$157	Hold	6,000	–	–	﹤0.01%	494
2021 Q2	$192	Hold	6,000	–	–	﹤0.01%	449
2021 Q1	$211	Hold	6,000	–	–	﹤0.01%	406
2020 Q4	$192K	Hold	6,000	–	–	﹤0.01%	445
2020 Q3	$226K	Hold	6,000	–	–	﹤0.01%	367
2020 Q2	$269K	Hold	6,000	–	–	﹤0.01%	337
2020 Q1	$205K	Hold	6,000	–	–	﹤0.01%	348
2019 Q4	$234K	Buy	+6,000	New	+$182K	﹤0.01%	436

Other funds holding RLMD

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Brown Brothers Harriman & Co's RLMD Position: Q4 2024 in Review

Brown Brothers Harriman & Co sold out of Relmada Therapeutics (RLMD) in Q4 2024, closing a stake of 3,000 shares — an estimated $9.72K sold.

Brown Brothers Harriman & Co first reported a position in RLMD in Q4 2019 and held it in 20 quarters. The position peaked at $269K in Q2 2020. 48 funds tracked by Wall St. Rank hold RLMD as of Q4 2024.

Brown Brothers Harriman & Co reported no remaining Relmada Therapeutics position as of Q4 2024 after selling out during the quarter.
Brown Brothers Harriman & Co sold 3,000 Relmada Therapeutics shares in Q4 2024, an estimated $9.72K.
Brown Brothers Harriman & Co first reported a position in Relmada Therapeutics in Q4 2019 and held it in 20 quarters.
Brown Brothers Harriman & Co's Relmada Therapeutics position peaked at $269K in Q2 2020.
48 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2024.

Based on Brown Brothers Harriman & Co's 13F filing for Q4 2024, filed 12 Feb 2025.